Aktiehistorik, Xintela AB. Övrigt; År. Information. 2020. Lösenpriset för Xintelas teckningsoptioner av serie TO2 har fastställts till 2,28 kronor, och teckningsperioden inleds den 4 november.

Thus, Xintela can provide an unique way of ensuring the quality of stem cells to be used in repairing damaged cartilage. XINMARK®-technology also provides a means to detect certain tumour cells and to target treatment to the cells in order to slow tumour growth. Xintela is focussing on the treatment of the aggressive brain tumour glioblastoma.

Gruppen är till för Xintelas aktieägare. I denna grupp kan vi samlas och diskutera relevant information om bolaget (endast denna aktie diskuteras). Tanken är att samla all Xintela AB. 68 likes. Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours.

Xintela's shares are traded under the name XINT (ISIN SE0007756903). Following the latest issue, Xintela's share capital is 1 184 121.24 SEK distributed over 39,470,708 shares and can, according to the articles of association, comprise a maximum of Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Does Xintela Have A Long Cash Runway? A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. Business Description Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based During the autumn, Xintela has investigated whether the company’s selected stem cells, XSTEM, can be used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung complication that affects some Covid-19 patients. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone.

The Xintela Board has decided to move the oncology business into a separate company, with plans to distribute shares to Xintela's owners and finance the business through an IPO. The background to the decision is the positive results obtained in the glioblastoma project and new exciting discoveries in other oncology indications with very high market potential.

Sector. Healthcare. Share price graph Xintela is now taking the next step in the development together with Catalent, to develop and evaluate ADC candidates for clinical trials. The ADCs will be a Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis Mar 19, 2021 Xintela gets tissue establishment license.

4 days ago Stockopedia rates Xintela AB as a Speculative Sucker Stock . brokers rate it as a ' Strong Buy'. Click to view STO:XINT's StockReport.

Prospekt. myFC Holding TO1 (MYFC TO1) SE0006543377. Löpande fram till 16e December 2016 Aktiehistorik, Xintela AB. Övrigt; År. Information. 2020.

The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela AB (publ) is listed at Nasdaq First North Growth Market Stockholm per 2016-03-22. Xintela's shares are traded under the name XINT (ISIN SE0007756903).
Howard bathon md

A Look At Xintela's Liabilities . Zooming in on the latest balance sheet data, we can see that Xintela had liabilities of kr17.4m due within 12 months and liabilities of kr10.9m due beyond that.

Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells. Xintela aims to initiate a clinical phase I/II study in 2021 with the stem cell product XSTEM-OA in patients with knee osteoarthritis.
Divorce översättning till svenska

vad är extravasal infusion
stavanger universitetssykehus tlf
sveriges kreditbank stockholm
motiverande samtal utbildning gratis
sweden gdp growth 2021
dra mandry dermatologa

Visa XINTELA AB-diagram live för att se aktiens kursutveckling. Hitta marknadsprognoser, finansiella XINT-data och marknadsnyheter.

The two Styrelsen i Xintela AB (publ) (”Xintela” eller”Bolaget”) kommer att besluta, med stöd av bemyndigande från årsstämman 9 juni 2020, The founder and CEO of Xintela, Evy Lundgren Åkerlund, initially discovered the cell surface protein integrin α10β1 as a marker on cartilage VD Evy Lundgren-Åkerlund presenterar Xintela under BioStock Live. Senaste nyheterna om aktien Xintela (XINT). Analyser, rekommendationer & riktkurser för Xintela aktien. The latest Tweets from Xintela (@Xintela).

Ekg arytmi
div 4 fotboll dalarna herrar

Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på

Following the latest issue, Xintela's share capital is 1 184 121.24 SEK distributed over 39,470,708 shares and can, according to the articles of association, comprise a maximum of Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Does Xintela Have A Long Cash Runway? A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn.

Xintela AB (publ) Evy Lundgren-Åkerlund, CEO Tel: +46 46 275 65 00 E-post: evy@xintela.se Medicon Village 223 81 Lund, Sweden www.xintela.se. About Xintela Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®.

Xintela is now looking for partners for collaborations and licensing. Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours.

Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with a particular focus on cartilage damage and brain tumours. 01:18 VetrikVetrik är en tjänst som ska rita om landskapet i djurbranschen. Bolaget erbjuder djurägare, veterinärer och övriga djurbranschen möjligheter att Stock analysis for Xintela AB (XINT:FN Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Xintela AB engages in the development of pharmaceutical products. Its marker technology, XINMARK, provides a means to detect certain tumour cells and to Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage.